Short answer
Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
Amneal Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued July 30, 2026
- Detailed financial results and management commentary in Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- Amneal scheduled a July 30, 2026 earnings call at 8:30 a.m. Eastern Time
- Investors can access the webcast and presentation through Amneal’s Investor Relations website
- Conference call replay availability enables review of management commentary after the event
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $796M, up 10%; Specialty grew 17% and Affordable Medicines 13%, indicating broad-based portfolio momentum
- GAAP net income $58M, up 157%; adjusted EBITDA $206M, up 12%; adjusted EPS $0.30, up 20%
- 2026 guidance raised to $3.10B-$3.20B revenue, $750M-$780M adjusted EBITDA, and $0.96-$1.06 adjusted EPS
- $2.084B Term Loan B repricing cuts spread 50 basis points, expected to save about $12M annually in cash interest
- Kashiv funding adds planned $350M Term Loan B, while net leverage reached 3.6x versus below-3.0x target by 2028
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amneal Pharmaceuticals, Inc. 8-K filings
Get the next AMRX 8-K as it lands
Follow AMRX for push alerts, or ask the research agent what this filing means.